Former RediClinic executive to speak at 2009 Health Technology Investment Forum
NEW YORK Former RediClinic executive Christopher Kersey is scheduled to speak about the future of health care at the 2009 Health Technology Investment Forum in September.
Kersey, former chief business development officer and chief medical officer of RediClinic, will join David Farber, JD, of Patton Boggs to address in their presentation entitled, “The Future of Healthcare: Unique Perspectives from the Investor and Policy Maker,” both the political forces shaping healthcare reform and the future of healthcare. Other topics that will be discussed include: substantive proposed changes affecting the healthcare industry, fee-for-service or bundled payments, and the most effective business models post-healthcare reform.
The forum, to be held Sept. 22, will attract such attendees as private equity firms, venture capital groups, corporate development teams, institutional investors and CEOs from healthcare technology companies.
Kersey, who currently works for Camden Partners, began his career as an associate at Menlo Ventures where he focused on healthcare and life science investments. He gained operational experience as the chief business development officer and chief medical officer of RediClinic. Prior to joining Camden Partners in 2008, he served as a managing director of Cogene Ventures.
Asteres to debut new automated pharmacy kiosk at NACDS Pharmacy & Technology Conference
SAN DIEGO A company that makes automated pharmacy kiosks plans to unveil its latest products at an upcoming conference.
Asteres, which makes the ScriptCenter kiosk, announced this week that it would debut ScriptCenter 24/7 Automated Pharmacy Services at the 2009 National Association of Chain Drug Stores Pharmacy & Technology Conference in Boston, which begins Saturday.
“To date, ScriptCenter has enabled retailers to reduce pharmacy hours and increase customer services,” Asteres CEO Mark de Bruin said in a statement. “The addition of 24/7 Automated Pharmacy Services will expand customer engagement opportunities and drive incremental store sales leveraging kiosk, online and cell technologies.”
The services include the Express Prescription Pickup, Prescription Drop Off Anytime, one-touch pickup for families, ScriptCenter.com and others.
Sciele Pharma announces availability of head lice treatment
NEW YORK A new drug for treating head lice has become available from a subsidiary of a Japanese drug company.
Sciele Pharma, part of Shionogi, announced this week the availability of Ulesfia (benzyl alcohol lotion 5%). The medication kills head lice by asphyxiation without potential neurotoxic side effects, the company said.
Head lice infestation affects 6 to 12 million children between the ages of 3 and 12 every year. To breathe, head lice use breathing holes that close upon contact with most liquids, which allows them to go into suspended animation and survive for hours without respiration, but Ulesfia prevents them from closing their breathing holes, causing the insects to asphyxiate.